Is ZYNTEGLO right for your patient?
≥12 years of age who do not have a β0/β0 genotype and who do not have an HLA-matched related donor.1
CONSIDER TREATMENT FOR PATIENTS WHO MEET THESE CRITERIA1:
Diagnosed with TDT
Who do not have a β0/β0 genotype
Patients ≥12 years of age
Appropriate for haematopoietic stem cell transplant (HSCT)
No human leukocyte antigen (HLA)–matched related haematopoietic stem cell donor available
- Hypersensitivity to the active substance or to any of the excipients
- Pregnancy and breastfeeding
- Previous treatment with HSC gene therapy
- Contraindications to the mobilisation agents and the myeloablative conditioning agent must be considered
Please consult the full EU Summary of Product Characteristics (EU SmPC) and the EU Abbreviated Prescribing Information (EU API) before prescribing.